Form 4: Marinus Pharmaceuticals Executive Receives Stock Options and Restricted Stock Units

Christina Shafer, Chief Commercial Officer of Marinus Pharmaceuticals, was granted stock options and restricted stock units on June 18, 2024.

Summary

• Christina Shafer, the Chief Commercial Officer of Marinus Pharmaceuticals, Inc., filed a Form 4 on June 20, 2024.
• The filing reports a transaction that occurred on June 18, 2024, where Shafer was granted 10,918 restricted stock units (RSUs) and options to purchase 49,125 shares of common stock.
• The RSUs vest in full on July 15, 2025, subject to continued service with Marinus Pharmaceuticals, Inc., with each RSU representing the right to receive one share of common stock.
• The stock options also vest and become exercisable in full on July 15, 2025, subject to continued service with the Issuer, at an exercise price of $1.40.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard executive compensation practices, aligning management interests with shareholders. There are no immediate negative implications.

Positives

• The grant of RSUs and stock options aligns the executive's interests with the long-term success of Marinus Pharmaceuticals.
• The vesting schedule encourages continued service and commitment from the Chief Commercial Officer.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the granted securities.

Industry Context

This type of equity compensation is common in the pharmaceutical industry to incentivize executives and align their interests with shareholders.

Comparison to Industry Standards

• Equity grants are a standard component of executive compensation packages in the pharmaceutical industry.
• Companies like Biohaven Pharmaceutical Holding Company Ltd and Sage Therapeutics Inc also use stock options and restricted stock units to incentivize their executives.
• The vesting schedules and exercise prices are generally in line with industry norms for similar-sized companies.

Stakeholder Impact

• Shareholders may view this as a positive sign, indicating that the company is investing in its leadership.
• Employees may see this as a sign of stability and commitment from the company to its executives.

Key Dates

Keywords

Form 4, Marinus Pharmaceuticals, MRNS, Christina Shafer, Chief Commercial Officer, Stock Options, Restricted Stock Units, RSUs, Beneficial Ownership, Vesting